MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 29, 2006; DOI: 10.1124/mol.106.028365


0026-895X/07/7101-145-157$20.00
Mol Pharmacol 71:145-157, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.028365v1
mol.106.028365v2
71/1/145    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, N. P.
Right arrow Articles by Nagarkatti, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, N. P.
Right arrow Articles by Nagarkatti, P. S.

Role of Dioxin Response Element and Nuclear Factor-{kappa}B Motifs in 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Regulation of Fas and Fas Ligand Expression

Narendra P. Singh, Mitzi Nagarkatti, and Prakash S. Nagarkatti

Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina

We have demonstrated previously that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) up-regulates Fas and FasL in immune cells, although the molecular mechanisms remain unknown. We investigated the regulation of Fas or FasL promoter by TCDD in EL4 T cells using luciferase reporter constructs. We observed 20 ± 5- and 14 ± 4-fold induction of promoter activity for Fas and FasL, respectively, after TCDD exposure. The induction of luciferase was significantly reduced (2 ± 1-fold) in the presence of {alpha}-naphthoflavone, an aryl hydrocarbon receptor (AhR) antagonist. We noted the presence of a dioxin response element (DRE) and five nuclear factor-{kappa}B (NF-{kappa}B) motifs on Fas promoter, and no DRE but two NF-{kappa}B motifs on FasL promoter. When we investigated the role of DRE and NF-{kappa}B, we observed varying levels of luciferase induction (9 ± 2-fold for DRE and 8 ± 2-fold for NF-{kappa}Bs of Fas promoter and 6 ± 3-fold for NF-{kappa}Bs of FasL promoter). Mutations in DRE of Fas promoter or NF-{kappa}Bs of FasL promoter led to decreased luciferase induction, further supporting our results. Probes for DRE or NF-{kappa}B motifs of Fas and/or FasL promoters demonstrated mobility shift in the presence of nuclear extract from TCDD-treated EL4 cells. Furthermore, we observed supershift in mobility when DRE and NF-{kappa}B probes were incubated in the presence of anti-mouse AhR, and anti-NF-{kappa}B (RelA/p65 and p50) antibodies, respectively. Administration of TCDD into mice caused significant increase in Fas and FasL transcripts in thymus and liver. These data demonstrate that TCDD regulates Fas and FasL promoters through DRE and/or NF-{kappa}B motifs via AhR.


Received for publication June 28, 2006.

Accepted for publication August 29, 2006.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
L. Bai, W. Chen, W. Chen, X. Wang, H. Tang, and Y. Lin
IKK{beta}-mediated nuclear factor-{kappa}B activation attenuates smac mimetic-induced apoptosis in cancer cells
Mol. Cancer Ther., June 1, 2009; 8(6): 1636 - 1645.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. Demetriades and G. Mosialos
The LMP1 Promoter Can Be Transactivated Directly by NF-{kappa}B
J. Virol., May 15, 2009; 83(10): 5269 - 5277.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Ishimaru, A. Takagi, M. Kohashi, A. Yamada, R. Arakaki, J. Kanno, and Y. Hayashi
Neonatal Exposure to Low-Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Causes Autoimmunity Due to the Disruption of T Cell Tolerance
J. Immunol., May 15, 2009; 182(10): 6576 - 6586.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. Detmar, M. Y. Rennie, K. J. Whiteley, D. Qu, Y. Taniuchi, X. Shang, R. F. Casper, S. L. Adamson, J. G. Sled, and A. Jurisicova
Fetal growth restriction triggered by polycyclic aromatic hydrocarbons is associated with altered placental vasculature and AhR-dependent changes in cell death
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E519 - E530.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Dong and F. Matsumura
Roles of Cytosolic Phospholipase A2 and Src Kinase in the Early Action of 2,3,7,8-Tetrachlorodibenzo-p-dioxin through a Nongenomic Pathway in MCF10A Cells
Mol. Pharmacol., July 1, 2008; 74(1): 255 - 263.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. P. Singh, M. Nagarkatti, and P. Nagarkatti
Primary Peripheral T Cells Become Susceptible to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin-Mediated Apoptosis in Vitro upon Activation and in the Presence of Dendritic Cells
Mol. Pharmacol., June 1, 2008; 73(6): 1722 - 1735.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. P. Singh, V. L. Hegde, L. J. Hofseth, M. Nagarkatti, and P. Nagarkatti
Resveratrol (trans-3,5,4'-Trihydroxystilbene) Ameliorates Experimental Allergic Encephalomyelitis, Primarily via Induction of Apoptosis in T Cells Involving Activation of Aryl Hydrocarbon Receptor and Estrogen Receptor
Mol. Pharmacol., December 1, 2007; 72(6): 1508 - 1521.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Z. Shi, N. G. Faith, Y. Nakayama, M. Suresh, H. Steinberg, and C. J. Czuprynski
The Aryl Hydrocarbon Receptor Is Required for Optimal Resistance to Listeria monocytogenes Infection in Mice
J. Immunol., November 15, 2007; 179(10): 6952 - 6962.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics